)
Lupin (500257) investor relations material
Lupin Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved 14th consecutive quarter of year-on-year growth, with consolidated Q3 FY26 revenue reaching INR 71,675.2 million, up 24%-26% year-on-year, and broad-based double-digit growth across most regions, including the U.S., India, Europe, LATAM, and emerging markets.
U.S. business delivered highest-ever sales, with North America sales up 46%-62% year-on-year, driven by new product launches (TOLVAPTAN, Risperdal Consta), exclusivity, and strong base business.
India prescription business grew 10.9% year-on-year, with chronic therapies now 67% of the portfolio and new divisions launched, including one for obesity.
Key product launches and regulatory approvals in the US and India, including pegfilgrastim biosimilar and gRisperdal Consta®, supported performance.
Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved by the Board on February 12, 2026.
Financial highlights
Q3 FY26 consolidated revenue from operations reached INR 71,675.2 million, up from INR 57,677.1 million in Q3 FY25; EBITDA for the quarter was INR 22,095 million, up 61.8% year-on-year, with a margin of 31.1%.
Net income for Q3 FY26 was INR 11,805.1 million, up 37.5% year-on-year, but down sequentially due to exceptional items.
Gross margin improved to 73.5% from 69.4% last year, driven by better product mix and lower share of in-licensed products.
Net cash stood at INR 2,879 crore as of December 31, 2025; net debt to equity remained low at 0.01.
Basic EPS (consolidated, before exceptional items) for Q3 FY26 was ₹32.97, up from ₹18.75 in Q3 FY25.
Outlook and guidance
Full-year EBITDA margin expected at 27%-28%, above earlier guidance of 25%-26%.
U.S. business expected to sustain $1 billion+ revenue with multiple new launches in injectables, biosimilars, and 505(b)(2) products over the next few years.
India business projected to outperform IPM by 1.2x-1.3x, supported by a strong sales force and robust pipeline.
R&D spend for the full year guided at 7.5%-8.5% of sales.
Plans to file 10-15 ANDAs in FY26, including two 505(b)(2) applications, and target 100+ new product launches by FY31.
Next Lupin earnings date
Next Lupin earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)